Total Clarity Wealth Management Inc. Takes $334,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Total Clarity Wealth Management Inc. acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,215 shares of the company’s stock, valued at approximately $334,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. J.W. Cole Advisors Inc. purchased a new stake in shares of TransMedics Group during the 2nd quarter worth $2,155,000. O Neil Global Advisors Inc. purchased a new stake in TransMedics Group during the second quarter worth about $1,604,000. Federated Hermes Inc. purchased a new stake in TransMedics Group during the second quarter worth about $3,349,000. Oppenheimer & Co. Inc. grew its position in TransMedics Group by 58.6% during the second quarter. Oppenheimer & Co. Inc. now owns 42,145 shares of the company’s stock worth $6,348,000 after buying an additional 15,575 shares during the period. Finally, Nicholas Investment Partners LP increased its holdings in TransMedics Group by 44.9% in the second quarter. Nicholas Investment Partners LP now owns 85,391 shares of the company’s stock valued at $12,862,000 after buying an additional 26,470 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Morgan Stanley boosted their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Piper Sandler lifted their price target on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. Finally, TD Cowen raised their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $171.44.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at approximately $109,770.72. The disclosure for this sale can be found here. In the last three months, insiders sold 52,622 shares of company stock worth $8,327,633. Insiders own 7.00% of the company’s stock.

TransMedics Group Trading Down 0.1 %

TransMedics Group stock opened at $151.21 on Tuesday. The stock has a 50-day moving average price of $154.24 and a 200 day moving average price of $127.46. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37. The stock has a market cap of $5.04 billion, a PE ratio of -444.74 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm’s revenue for the quarter was up 117.7% compared to the same quarter last year. During the same period last year, the company earned ($0.03) EPS. Equities research analysts predict that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.